194 related articles for article (PubMed ID: 28420840)
1. Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.
Matano D; Moriwaki T; Tange Y; Niisato Y; Yamaura M; Nagase M; Suganuma D; Takagi Taketa K; Iwai K; Enami C; Yamamoto Y; Hyodo I
Intern Med; 2017; 56(8):921-923. PubMed ID: 28420840
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
7. [A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
Morifuji M; Murakami Y; Yokoyama Y; Sasaki M; Hayashidani Y; Toge K; Sueda T
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2027-30. PubMed ID: 15570933
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
Seo S; Suzuki T; Misumi T; Tashiro H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1305-1307. PubMed ID: 29394615
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
Sato S; Kunisaki C; Tanaka Y; Sato K; Miyamoto H; Yukawa N; Fujii Y; Kimura J; Takagawa R; Takahashi M; Kosaka T; Akiyama H; Saigusa Y; Taguri M; Yamanaka T; Endo I
Anticancer Res; 2018 Dec; 38(12):6911-6917. PubMed ID: 30504409
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
14. [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Ohashi M; Kanda T; Yajima K; Banba T; Tanabe T; Kosugi S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1640-2. PubMed ID: 16315894
[TBL] [Abstract][Full Text] [Related]
15. [A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
Urano S; Kakiuchi Y; Takashima H
Gan To Kagaku Ryoho; 2016 Feb; 43(2):251-4. PubMed ID: 27067693
[TBL] [Abstract][Full Text] [Related]
16. [A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Seshimo K; Kanagawa T; Yamashita Y; Oishi M; Kodera M; Yamamura M; Katoh H; Ikeda H; Yokomichi N; Kobayashi K; Takita K
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1741-4. PubMed ID: 19838039
[TBL] [Abstract][Full Text] [Related]
17. [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
Kato K; Koide A; Oobu M; Hasegawa K; Maruyama S; Takashima I; Nagahama T; Maruyama M; Ebuchi M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1852-4. PubMed ID: 15553737
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
19. [A case of advanced gastric cancer with peritoneal metastases responding to bi-weekly paclitaxel therapy].
Yamaguchi Y; Taniguchi K; Naka T; Shibata S; Ishiguro M; Yurugi E; Nishidoi H; Kudoh H; Murakami S
Gan To Kagaku Ryoho; 2003 Apr; 30(4):527-30. PubMed ID: 12722687
[TBL] [Abstract][Full Text] [Related]
20. [Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
Fujii K; Uno H; Kayo S; Ueda Y; Kawamura C; Mizuyama Y; Kaneda K; Nakagawa H; Arakawa T
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1107-9. PubMed ID: 17637550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
